View on Pubmed.gov 42998545 | View on doi.org 10.1016/j.jns.2... | View the free full text Full text
The prognostic role of echocardiographic parameters in ischemic stroke patients with atrial fibrillation.
- Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Switzerland.
- Department of Cardiology, University Hospital Basel, Basel, Switzerland.
- Clinical Trial Unit, Department of Clinical Research, University Hospital Basel and University of Basel, Switzerland.
- Department of Intensive Care Medicine, University Hospital Basel, Switzerland.
- Department of Neuroradiology, University Hospital Basel, Basel, Switzerland.
- Department of Neurology and Stroke Center, Inselspital, Bern, Switzerland.
- Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Switzerland; Department of Rehabilitation and Neurology, University Department of Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland.
- Department of Neurology and Stroke Center, University Teaching and Research Hospital, Health Eastern Switzerland (HOCH), Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
- Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Switzerland; Research Department, Reha Rheinfelden, Rheinfelden, Switzerland.
- Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Switzerland; Department of Rehabilitation and Neurology, University Department of Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland; Stroke Center, Klinik Hirslanden, Zürich, Switzerland. Electronic address: nils.peters@unibas.ch.
Abstract
BACKGROUND
Concomitant cerebral small vessel disease (cSVD) in stroke patients with atrial fibrillation (AF) is associated with an unfavourable outcome, but the additional prognostic value of echocardiographic parameters remains unclear.
METHODS
We included consecutive patients with recent AF-associated ischemic stroke (IS) or transient ischemic attack (TIA) who underwent echocardiography and brain MRI from the prospective Novel Oral Anticoagulants in Ischemic Stroke Patients registry. We examined associations of left atrial and ventricular echocardiographic parameters with a primary composite outcome (recurrent IS; intracranial hemorrhage, all-cause death) and its components as secondary outcomes, using unadjusted and adjusted (age, sex, modified CHA 2DS 2VASc-Score, hyperlipidemia, oral anticoagulation before/after stroke, MRI markers of cSVD) Cox regression. Associations between echocardiographic parameters and MRI markers of cSVD were analyzed using logistic regression.
RESULTS
We included 690 patients (median age 80, 45% female) with a total follow-up of 1084 patient-years. In unadjusted analyses, left ventricular hypertrophy (LVH) was associated with the composite outcome (HR 1.44 [1.05-1.97]) and all-cause death (HR 1.95 [1.33-2.84]), neither association persisted after adjustment (aHR 1.04 [0.74-1.46]; aHR 1.29 [0.85-1.96]) Reduced ejection fraction and concentric/eccentric hypertrophy were associated with all-cause death in unadjusted analysis only. No echocardiographic parameter was associated with recurrent IS. Left atrial dilatation (OR 1.96 [1.32-2.91]) and concentric hypertrophy were associated (OR 1.68 [1.08-2.62]) with white matter hyperintensities extent in unadjusted but not in adjusted analyses.
CONCLUSION
In stroke patients with AF, structural changes of the left ventricle might be considered as indicator but not independent predictor of future cerebrovascular events or death.
CLINICAL TRIAL REGISTRATION
NCT03826927.
References
Conflict of interest statement
Declaration of competing interest AZ, LH, VA, JK, BW, SS; ST, JF, PL, JF, STE, LHB, BK, JL, DS, CT, HG, GMDM and NP report no COI. TDD was or is supported by the Swiss Heart Foundation, the science funds of the University Hospital Basel, and the Research fund for excellent young researchers of the University of Basel. He holds shares from Johnson&Johnson, Roche, Lilly, Bristol-Myers Squibb, Merck, and Novo Nordisk. He received a personal travel grant from OM Pharma. MK reports research support from the Swiss National Science Foundation (32NE30_213471, 32003B_182267), Swiss Heart Foundation, USZ Foundation, SAMW and HORIZON (101172825). As Honoraria/Speakers Bureaus/Ad.Boards MK reports: Astra Zeneca, Medtronic, Jansen/MS/Pfizer, Bayer and Novartis. UF reported research support of the Swiss National Science Foundation and the Swiss Heart Foundation. PI of the ELAN trial, Co-PI of the DISTAL, TECNO, SWIFT DIRECT, SWITCH, ELAPSE and ICARUS trial. Research grants from Medtronic (BEYOND SWIFT, SWIFT DIRECT) and from Stryker, Rapid medical, Penumbra, Medtronic and Phenox (DISTAL), Boehringer Ingelheim (TECNO). Consultancies for Medtronic (fees paid to institution). Participation in an advisory board for AstraZeneca (former Alexion/Portola), Bayer, Boehringer Ingelheim, Biogen, AbbVie, Siemens (fees paid to institution). Member of a clinical event committee (CEC) of the COATING study (Phenox). Member of the data and safety monitoring committee (DSMB) of the TITAN, LATE_MT, IN EXTREMIS and RapidPulse trials. President of the Swiss Neurological Society and president-elect of the European Stroke Organisation.
MeSH
- •
- •
- •
- •
Specialties
- •
Copyright
Copyright © 2026 Elsevier B.V. All rights reserved.